Advancements in NSCLC: From Pathophysiological Insights to Targeted Treatments
J Xu, L Tian, W Qi, Q Lv, T Wang - American Journal of Clinical …, 2024 - journals.lww.com
With the global incidence of non-small cell lung cancer (NSCLC) on the rise, the
development of innovative treatment strategies is increasingly vital. This review underscores …
development of innovative treatment strategies is increasingly vital. This review underscores …
Mechanisms of resistance to tyrosine kinase inhibitor‐targeted therapy and overcoming strategies
X Ou, G Gao, IA Habaz, Y Wang - MedComm, 2024 - Wiley Online Library
Tyrosine kinase inhibitor (TKI)‐targeted therapy has revolutionized cancer treatment by
selectively blocking specific signaling pathways crucial for tumor growth, offering improved …
selectively blocking specific signaling pathways crucial for tumor growth, offering improved …
Exploiting a tumor softening targeted bomb for mechanical gene therapy of chemoresistant Triple-Negative breast cancer
Y Shen, X Guan, S Li, X Hou, J Yu, H Yin… - Chemical Engineering …, 2024 - Elsevier
Triple-negative breast cancer (TNBC)-the most aggressive and refractory subtype of breast
cancer-plagues many patients. The tumor physical microenvironment (TPME) is …
cancer-plagues many patients. The tumor physical microenvironment (TPME) is …
Icotinib in a lung adenocarcinoma patient with acquired EGFR 19del/C797S mutation-mediated resistance to osimertinib: a case report
F Cai, Y Zhao, S Song, D Zhao, Z Zheng… - Anti-Cancer Drugs, 2024 - journals.lww.com
Based on the FLAURA and AURA III trials, compared to first-and second-generation
epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs), osimertinib …
epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs), osimertinib …
Anlotinib in patients with recurrent platinum resistant/refractory ovarian cancer: a prospective, single arm, phase II study
W Shen, C Jing, W Tian, W Zhang, Y Ren… - International Journal of …, 2023 - ijgc.bmj.com
Objective This study aimed to prospectively evaluate the efficacy and safety of anlotinib in
patients with platinum resistant/refractory ovarian cancer. Methods In this prospective, single …
patients with platinum resistant/refractory ovarian cancer. Methods In this prospective, single …
[PDF][PDF] 安罗替尼联合吉非替尼一线治疗EGFR 阳性的晚期非小细胞肺癌的临床效果分析
刘玮萱 - 中国医学创新 - zgyxcx.com
目的: 探索抗血管生成药物安罗替尼联合吉非替尼一线用于治疗晚期EGFR 敏感突变的非小细胞
肺癌患者的临床效果和安全性. 方法: 选取2019 年5 月—2021 年2 月于连云港市第一人民医院 …
肺癌患者的临床效果和安全性. 方法: 选取2019 年5 月—2021 年2 月于连云港市第一人民医院 …
Antiangiogenic therapy: how far is it to upgrade?
J Wang, K Li - Holistic Integrative Oncology, 2024 - Springer
Early vascular-targeted drugs represented by VEGF single-pathway inhibitors pioneered the
idea of regulating the tumor growth microenvironment and enhanced the chemotherapy …
idea of regulating the tumor growth microenvironment and enhanced the chemotherapy …
[PDF][PDF] Case Report: Anlotinib For Advanced Non-Small Cell Lung Cancer That Has Not Responded To First-And Second-Line Therapy
X Li - Annals of Clinical and Medical Case Reports, 2024 - acmcasereports.org
Primary bronchial lung cancer, referred to as lung cancer, is one of the malignant tumors
with high morbidity and mortality in China and other countries in the world, accounting for …
with high morbidity and mortality in China and other countries in the world, accounting for …
[HTML][HTML] Professor Li Gaofeng's group manuscript| Luo Xiangchong: The most complete summary of the first-line treatment strategies for patients with advanced …
L Xiangchong - laitimes.com
Editor's note: At present, EGFR-TKIs have significantly improved the treatment landscape of
patients with EGFR-sensitive mutations in advanced NSCLC, and EGFR-TKIs monotherapy …
patients with EGFR-sensitive mutations in advanced NSCLC, and EGFR-TKIs monotherapy …